Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 38%
Hold 10%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is positioned for significant growth, driven by key momentum factors such as Medicare expansion, which is expected to enhance coverage and patient access through clinical data expected in 2026, and additional wins in the NIT segment that will broaden the number of covered lives. The company's innovative product pipeline, including the improved G7 sensor and the introduction of SmartBasal, indicates strong potential for increasing adoption and usage among diabetic patients. With operational efficiency improvements leading to better gross margins and projected revenue growth in the mid-teens alongside EPS growth exceeding 20% through 2028, DexCom's financial outlook remains robust.

Bears say

DexCom's financial performance indicates a concerning trend with hardware revenue declining sharply by 31% year-over-year, while overall revenue guidance for FY26 falls slightly short of market expectations, suggesting potential challenges ahead. Additionally, the anticipated sequential revenue decline of 6-7% in Q1 2026 highlights a decelerating growth trajectory, exacerbated by changes in the company's sales seasonality and an increasing reliance on pharmacy distribution. Compounding these issues, the company's inability to substantively improve its competitive standing amidst recent US growth slowdowns and execution difficulties raises doubts about the stock's valuation compared to its peers.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 38% recommend Buy, 10% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Apr 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.